Newsletters and Deep Dive digital magazine
Celgene has added another new indication for its blood cancer blockbuster Revlimid, with the FDA approving its use alongside Roche’s Rituxan for two additional forms of indolent non-Hodgkin
The FDA has approved Genentech’s Rituxan (rituximab) for use in adults with moderate-to-severe pemphigus vulgaris (PV), making it the first treatment for the condition in more than 60 years.
German biotech 4SC has filed its oral HDAC inhibitor Kinselby with the EMA, hoping to provide a much-needed new therapy for patients with the rare cancer cutaneous T-Cell
Today, pharma brand planning teams can benefit from technology platforms that aggregate data and automate analyses, helping unlock insights on the market landscape and clinical environment